drugset
drugset / Trial / NCT02807844

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

NCT02807844 ↗

Phase 1/2 Completed 141 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study of MCS110 with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.

Timeline

Start
2016-06-29
Primary completion
2020-06-04
Completion
2020-06-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MCS110 Monoclonal antibody 1 mg/kg Intravenous
Subject MCS110 Monoclonal antibody 3 mg/kg Intravenous
Subject MCS110 Monoclonal antibody 5 mg/kg Intravenous
Subject MCS110 Monoclonal antibody 7.5 mg/kg Intravenous
Subject MCS110 Monoclonal antibody 10 mg/kg Intravenous
Subject Spartalizumab Monoclonal antibody 100 mg Intravenous
Subject Spartalizumab Monoclonal antibody 300 mg Intravenous

Indications

endometrial carcinoma melanoma triple-negative breast carcinoma